Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Fosfocreatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosfocreatine SCHEMBL9075223 | 0.98 | MVD (0.39) | MVDNOS3NOS1NOS2CA1 | |
| Fosfocreatine SCHEMBL5248692 | 0.98 | MVD (0.39) | MVDNOS3NOS1NOS2CA1 | |
| Fosfocreatine SCHEMBL2635002 | 0.92 | MVD (0.42) | MVD | |
| Fosfocreatine SCHEMBL24116748 | 0.90 | MVD (0.44) | MVD | |
| Fosfocreatine SCHEMBL2124030 | 0.90 | MVD (0.44) | MVD | |
| Fosfocreatine SCHEMBL65425 | 0.90 | MVD (0.44) | MVD | |
| Creatine SCHEMBL27189 | 0.87 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL10710660 | 0.87 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL4110519 | 0.87 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 | |
| Creatine SCHEMBL2817384 | 0.87 | MVD (0.42) | MVDNOS3NOS1NOS2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064179-A1 | BICARBONATE SOLUTION FOR BIOAVAILABLE MAGNESIUM AND USES THEREOF | UNIQUE GLOBAL POSSIBILITIES MEDICAL PTY LIMITED (AU) | 2012-03-15 | — | — | US | claimed |
| EP-1964860-B1 | ETHYLENE POLYMER, CATALYST FOR PRODUCTION OF ETHYLENE POLYMER, AND PROCESS FOR PRODUCTION OF ETHYLENE POLYMER | TOSOH CORP (JP) | 2017-07-05 | — | — | EP | disclosed |
| EP-1473323-B1 | Polyethylene composition and process for producing same | TOSOH CORP (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-8871885-B2 | Ethylene-a-olefin copolymer and molded article | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8841396-B2 | Ethylene-α-olefin copolymer and molded article | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8809462-B2 | Ethylene-α-olefin copolymer, molded article, catalyst for copolymerization, and method for producing an ethylene-α-olefin copolymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20130324691-A1 | Ethylene-a-Olefin Copolymer and Article | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-12-05 | — | — | US | disclosed |
| US-8501891-B2 | Ethylene-α-olefin copolymer and molded article | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20130005930-A1 | ETHYLENE-alpha-OLEFIN COPOLYMER AND MOLDED ARTICLE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-01-03 | — | — | US | disclosed |
| US-20120123006-A1 | RESIN COMPOSITION FOR CROSSLINKING/FOAM MOLDING, CROSSLINKED MOLDED FOAM, MEMBER FOR FOOTWEAR, AND FOOTWEAR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20110040059-A1 | ETHYLENE-a-OLEFIN COPOLYMER AND MOLDED ARTICLE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110021632-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110008272-A1 | Use of Creatine or Creatine Compounds for Skin Preservation | AVICENA GROUP, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100310799-A1 | ETHYLENE-a-OLEFIN COPOLYMER AND MOLDED ARTICLE | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-12-09 | — | — | US | disclosed |
| US-20100305292-A1 | ETHYLENE-a-OLEFIN COPOLYMER AND MOLDED ARTICLE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-02 | — | — | US | disclosed |
| US-7838611-B2 | Ethylene polymer, catalyst for ethylene polymer production, and method for producing ethylene polymer | TOSOH CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-7678866-B2 | Polyethylene composition and process for producing same | TOSOH CORPORATION (JP) | 2010-03-16 | — | — | US | disclosed |
| US-20090137755-A1 | ETHYLENE POLYMER, CATALYST FOR ETHYLENE POLYMER PRODUCTION, AND METHOD FOR PRODUCING ETHYLENE POLYMER | TOSOH CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1473323-A1 | Polyethylene composition and process for producing same | Tosoh Corporation (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20040214953-A1 | Polyethylene composition and process for producing same | TOSOH CORPORATION | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008272-A1 | Use of Creatine or Creatine Compounds for Skin Preservation | PC, CKMT1A; CKMT1B, CHEK1 | MVD 1793/4885NOS3 2632/4885NOS1 4211/4885 |
| US-20110021632-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | MVD 1793/4885NOS3 2632/4885NOS1 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.